Secretion of cortisol and aldosterone as a vulnerable target for adrenal endocrine disruption - Screening of 30 selected chemicals in the human H295R cell model

Journal of Applied Toxicology

Volumn 28, Issue 8, 2008, Pages 1045-1053

  Ullerås, Erik ^a   Ohlsson, Åsa ^a   Oskarsson, Agneta ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Adrenal; Aldosterone; Angiotensin; Cortisol; Endocrine disruptor; Forskolin; H295R; Steroidogenesis

Indexed keywords

2 BROMO ALPHA ERGOCRIPTINE METHANESULFONATE; 6 HYDROXYFLAVONE; ALDOSTERONE; AMINOGLUTETHIMIDE; ANGIOTENSIN II; ARSENITE SODIUM; ATRAZINE; BETA NAPHTHOFLAVONE; CADMIUM CHLORIDE; DAIDZEIN; DIETHYLUMBELLIFERYL PHOSPHATE; DIMETHOATE; ENDOCRINE DISRUPTOR; ENILCONAZOLE; ETOMIDATE; FLUTAMIDE; FORSKOLIN; HYDROCORTISONE; KETOCONAZOLE; LITHIUM CHLORIDE; METYRAPONE; MITOTANE; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PROCHLORAZ; RESVERATROL; SEX HORMONE; SILYMARIN; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCLOZOLIN;

ADRENAL CORTEX CELL; ADRENAL GLAND; ALDOSTERONE RELEASE; ARTICLE; CELL LINE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYDROCORTISONE RELEASE; IN VITRO STUDY; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE ANALYSIS; SCREENING; STEROIDOGENESIS;

ADRENAL GLANDS; ALDOSTERONE; ANGIOTENSIN II; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DIMETHYL SULFOXIDE; ENDOCRINE DISRUPTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORSKOLIN; HUMANS; HYDROCORTISONE; SOLVENTS; TOXICITY TESTS;

EID: 55549111623     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1371     Document Type: Article

References (27)

1. Bergman A, Wachtmeister CA. 1977. Synthesis of methanesulfonyl derivatives of 2,2-bis (4-chlorophenyl)-1,1-dichloroethylene (p,p′-DDE), present in seal from the Baltic. Acta Chem. Scand. B 31: 90-91.
2. Bird IM, Hanley NA, Word RA, Mathis JM, McCarthy JL, Mason JI, Rainey WE. 1993. Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. Endocrinology 133: 1555-1561.
3. Fassnacht M, Beuschlein F, Vay S, Mora P, Allolio B, Reincke M. 1998. Aminoglutethimide suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor cell line. J. Endocrinol. 159: 35-42.
4. Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV. 1990. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 50: 5488-5496.
5. Goldman JM, Murr AS. 2002. Alterations in ovarian follicular progesterone secretion by elevated exposures to the drinking water disinfection byproduct dibromoacetic acid: examination of the potential site(s) of impact along the steroidogenic pathway. Toxicology 171: 83-93.
6. Gross BA, Mindea SA, Pick AJ, Chandler JP, Batjer HH. 2007. Medical management of Cushing disease. Neurosurg. Focus 23: E10.
7. Harvey PW, Everett DJ. 2003. The adrenal cortex and steroidogenesis as cellular and molecular targets for toxicity: critical omissions from regulatory endocrine disrupter screening strategies for human health? J. Appl. Toxicol. 23: 81-87.
8. Harvey PW, Everett DJ, Springall CJ. 2007. Adrenal toxicology: a strategy for assessment of functional toxicity to the adrenal cortex and steroidogenesis. J. Appl. Toxicol. 27: 103-115.
9. He Y, Murphy MB, Yu RM, Lam MH, Hecker M, Giesy JP, Wu RS, Lam PK. 2008. Effects of 20 PBDE metabolites on steroidogenesis in the H295R cell line. Toxicol. Lett. 176: 230-238.
10. Hecker M, Giesy JP. 2008. Novel trends in endocrine disruptor testing: the H295R Steroidogenesis Assay for identification of inducers and inhibitors of hormone production. Anal. Bioanal. Chem. 390: 287-291.
11. Hecker M, Newsted JL, Murphy MB, Higley EB, Jones PD, Wu R, Giesy JP. 2006. Human adrenocarcinoma (H295R) cells for rapid in vitro determination of effects on steroidogenesis: hormone production. Toxicol. Appl. Pharmac. 217: 114-124.
12. Hecker M, Hollert H, Cooper R, Vinggaard AM, Akahori Y, Murphy M, Nellemann C, Higley E, Newsted J, Wu R, Lam P, Laskey J, Buckalew A, Grund S, Nakai M, Timm G, Giesy J. 2007. The OECD validation program of the H295R steroidogenesis assay for the identification of in vitro inhibitors and inducers of testosterone and estradiol production. Phase 2: Inter-laboratory pre-validation studies. Environ. Sci. Pollut. Res. 14 (special issue 1): 23-30.
13. Hinson JP, Raven PW. 2006. Effects of endocrine-disrupting chemicals on adrenal function. Best Pract Res Clin Endocrinol Metab. 20: 111-120.
14. Johansson MK, Sanderson JT, Lund BO. 2002. Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol. in Vitro 16: 113-121.
15. Ledingham IM, Watt I. 1983. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1: 1270.
16. Li LA, Wang PW. 2005. PCB126 induces differential changes in androgen, cortisol, and aldosterone biosynthesis in human adrenocortical H295R cells. Toxicol. Sci. 85: 530-540.
17. Muller-Vieira U, Angotti M, Hartman RW. 2005. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors. J. Steroid Biochem. Mol. Biol. 96: 259-270.
18. Oskarsson A, Ullerås E, Plant KE, Hinson JP, Goldfarb PS. 2006. Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro. J. Appl. Toxicol. 26: 484-492.
19. Rainey WE, Bird IM, Sawetawan C, Hanley NA, McCarthy JL, McGee EA, Wester R, Mason JI. 1993. Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. J. Clin. Endocrinol. Metab. 77: 731-737.
20. Rainey WE, Bird IM, Mason JI. 1994. The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. Mol. Cell Endocrinol. 100: 45-50.
21. Rainey WE, Saner K, Schimmer BP. 2004. Adrenocortical cell lines. Mol. Cell Endocrinol. 228: 23-38.
22. Ribelin WE. 1984. The effects of drugs and chemicals upon the structure of the adrenal gland. Fundam. Appl. Toxicol. 4: 105-119.
23. Rosol TJ, Yarrington JT, Latendresse J, Capen CC. 2001. Adrenal gland: structure, function, and mechanisms of toxicity. Toxicol Pathol. 29: 41-48.
24. Samandari E, Kempná P, Nuoffer JM, Hofer G, Mullis PE, Flück CE. 2007. Human adrenal corticocarcinoma NCI-H295R cells produce more androgens than NCI-H295A cells and differ in 3beta-hydroxysteroid dehydrogenase type 2 and 17,20 lyase activities. J. Endocrinol. 195: 459-472.
25. Sanderson JT, Boerma J, Lansbergen GW, van den Berg M. 2002. Induction and inhibition of aromatase (CYP19) activity by various classes of pesticides in H295R human adrenocortical carcinoma cells. Toxicol. Appl. Pharmac. 182: 44-54.
26. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. 1984. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. New Engl. J. Med. 310: 1415-1421.
27. Ziolkowska A, Belloni AS, Nussdorfer GG, Nowak M, Malendowicz LK. 2006. Endocrine disruptors and rat adrenocortical function: studies on freshly dispersed and cultured cells. Int. J. Mol. Med. 18: 1165-1168.